Slide 1: Fiscal Second Quarter Ended June 30, 2022 Earnings Presentation
Fiscal Second Quarter Ended June 30, 2022 Earnings Presentation July 29, 2022
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hop
Slide 3: Key Messages
Key Messages Year-to-date order1 growth of 25% compared to same period last year, both Medical and Industrial end markets are healthy Nuclear macro trends continue with positive momentum, manifesting in order book and notable commercial wins Medical business delivering strong double-digit revenue an
Slide 4: Market Performance Update
Market Performance Update End market trends materializing in order book and growth CY21 % Market YTD Order Segment and End Market Commentary and Trends of Total Growth1 Growth2 Medical | CY21 Revenue ~$228M 34% of Total • Strong domestic hardware orders and long-term service agreements Radiation The
Slide 5: Fiscal Second Quarter Ended June 30, 2022 Summary
Fiscal Second Quarter Ended June 30, 2022 Summary Great Medical momentum, Industrial challenged in the quarter YTD order growth of 25% compared to same period in 20211 Adjusted Revenue Performance 3-months ended Jun. 30, 2022 vs. Jun. 30, 2021 $ millions Adjusted EPS of $0.13 for second quarter of 2
Slide 6: Mirion | Fiscal Second Quarter Ended
Mirion | Fiscal Second Quarter Ended June 30, 2022 Adjusted Revenue Adjusted EBITDA and Margin Adjusted Gross Profit Margin Adjusted EPS $ millions | % percentage $ millions | % percentage % percentage | basis points $ millions % 2Q21 vs. 2Q22 Public company costs of ~$3.3M Organic -1.7% in Q2 2022
Slide 7: Medical | Fiscal Second Quarter Ended
Medical | Fiscal Second Quarter Ended June 30, 2022 Adjusted Revenue Adjusted EBITDA and Margin MEDICAL SEGMENT $ millions | % percentage $ millions | % percentage Nuclear Medicine % 2Q21 vs. 2Q22 Radiotherapy Organic +15.1% Medical Imaging +38.8% Occupational Dosimetry Acquisition +5.8% FX -1.3% $2
Slide 8: Industrial | Fiscal Second Quarter Ended
Industrial | Fiscal Second Quarter Ended June 30, 2022 Adjusted Revenue Adjusted EBITDA and Margin INDUSTRIAL SEGMENT $ millions | % percentage $ millions | % percentage Nuclear Power % 2Q21 vs. 2Q22 Labs & Research Organic -9.0% Defense & Diversified Industrial Acquisition n.a. -22.0% Supply chain
Slide 9: Leverage, Liquidity and Adjusted Free Cash Flow
Leverage, Liquidity and Adjusted Free Cash Flow As of June 30, 2022 Leverage Liquidity and Adjusted Free Cash Flow • Cash on hand as of June 30, 2022 of $91M • Total liquidity available of $167M incl. undrawn revolver of $76M • Revolving facility includes springing first lien net leverage • Investme
Slide 10: Updated Guidance for the 12 Months Ending December 31, 2022
Updated Guidance for the 12 Months Ending December 31, 2022 Reiterating 2022 organic growth and Adjusted EBITDA expectations Category1 July 29, 2022 May 4, 2022 What we are seeing and expectations Reported Adj. Revenue Growth 2% to 4% 3.5% to 5.5% • FX continues to be a headwind vs. prior year, prim
Slide 11: Mirion Second Quarter 2022 Key Takeaways
Mirion Second Quarter 2022 Key Takeaways Outstanding order performance supports short and mid-term revenue targets Nuclear trends continue with positive momentum, manifesting in order book and key commercial wins Supply chain showed some signs of improvement, but challenges persist and are expected
Slide 12: Appendix
Appendix &
Slide 13: Backlog Trend | Q2 CY20 to Q2 CY22
Backlog Trend | Q2 CY20 to Q2 CY22 $ millions Hanhikivi Backlog Excl Hanhikivi $766 $754 $738 $79 $716 $703 $67 $693 $69 $79 $72 $637 $621 $601 $78 $687 $669 $687 $693 $637 $631 $559 Q2 CY20 Q3 CY20 Q4 CY20 Q1 CY21 Q2 CY21 Q3 CY21 Q4 CY21 Q1 CY22 Q2 CY22 Note: Backlog figures on an as reported basis
Slide 14: Nine Quarter Segment Reconciliation – Medical
Nine Quarter Segment Reconciliation Medical Combined Successor (non-GAAP) Predecessor ($ in millions) Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Revenue $ 66.8 $ 60.1 $ 57.5 $ 52.0 $ 52.1 $ 51.5 $ 31.7 $ 20.4 $ 18.1 Revenue reduction from purchase accounting - - 3.1 3.7
Slide 15: Nine Quarter Segment Reconciliation – Industrial
Nine Quarter Segment Reconciliation Industrial Combined Successor (non-GAAP) Predecessor ($ in millions) Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Revenue $ 109.0 $ 103.1 $ 120.3 $ 92.3 $ 127.9 $ 114.7 $ 119.0 $ 94.2 $ 123.0 Revenue reduction from purchase accounting -
Slide 16: Nine Quarter Segment Reconciliation – Corporate & Other
Nine Quarter Segment Reconciliation Corporate & Other Combined Successor (non-GAAP) Predecessor ($ in millions) Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Revenue $ - $ - $ - $ - $ - $ - $ - $ - $ - Revenue reduction from purchase accounting - - - - - - - - - Adjusted Re
Slide 17: Nine Quarter Segment Reconciliation – Consolidated
Nine Quarter Segment Reconciliation Consolidated Combined Successor (non-GAAP) Predecessor ($ in millions) Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021 Q4 2020 Q3 2020 Q2 2020 Revenue $ 175.8 $ 163.2 $ 177.8 $ 144.3 $ 180.0 $ 166.2 $ 150.8 $ 114.6 $ 141.2 Revenue reduction from purchase accountin
Slide 18: Non-GAAP Reconciliations
Non-GAAP Reconciliations Consolidated – Income (loss) from Operations, Adjusted Gross Profit & Adjusted EBITDA Three Months Ended Three Months Ended June 30, 2022 June 30, 2021 ($ in millions) (Successor) (Predecessor) Net income (loss) before minority interest $ (59.3) $ (54.0) Interest expense, ne
Slide 19: Non-GAAP Reconciliations – Adjusted Earnings per Share
Non-GAAP Reconciliations Reconciliation of Adjusted Earnings per Share Three Months Ended June 30, 2022 ($ in millions) (Successor) Net loss attributable to Mirion Technologies, Inc. (Successor) / Mirion Technologies (TopCo), Ltd. (Predecessor) stockholders $ (58.6) Loss attributable to noncontrolli
Slide 20: Share Count Details
Share Count Details As of June 30, 20221 Outstanding Fully Diluted Share Description Securities (Illustrative)2,3,4 Notes Shares of Class A Common Stock – Public 181,304,646 181,304,646 Outstanding shares as of close of trading on the New York Stock Exchange (NYSE) June 30, 2022 Shares for EPS Cal
Slide 21: Footnotes to Share Count and Adjusted Metrics
Footnotes to Share Count and Adjusted Metrics Share Count Consists of 181,304,646 shares of Class A common stock and 8,060,540 shares of Class B common stock outstanding as of June 30, 2022. Excludes (1) 18,750,000 founder shares which are shares of Class A common stock subject to vesting in three e
Slide 22: Mirion Technologies
m MIRION TECHNOLOGIES MIR LISTED NYSE